Francis deSouza, Illumina CEO (Photographer: Kyle Grillot/Bloomberg via Getty Images)

As Il­lu­mi­na dis­ap­points Wall Street, com­peti­tors make their case at JPM

Last Sep­tem­ber, Il­lu­mi­na pledged to de­ci­pher a per­son’s ge­net­ic code for as lit­tle as $200 with its new se­quenc­ing ma­chines, part of a wider push to make ge­net­ic test­ing a rou­tine part of check-ups.

At the JP Mor­gan Health­care Con­fer­ence on Wednes­day, com­peti­tor El­e­ment Bio­sciences said its tech­nol­o­gy could al­so se­quence a genome for $200 – and po­ten­tial­ly with ma­chines that cost less.

“Our goal is to de­moc­ra­tize se­quenc­ing by dri­ving down costs,” said El­e­ment CEO Mol­ly He.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.